9. CalciMedica Inc. (NASDAQ:CALC)
Number of Hedge Fund Holders: 6
CalciMedica Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for life-threatening inflammatory diseases with high unmet needs. Their proprietary technology targets the inhibition of calcium release-activated calcium channels, aiming to modulate immune responses and protect against tissue cell injury. The company’s lead product candidate is an intravenous formulation of a small molecule CRAC channel inhibitor, which is currently in development for the treatment of acute pancreatitis with systemic inflammatory response syndrome and asparaginase-associated pancreatitis. There are currently no approved disease-modifying treatments for these conditions. CALC’s approach offers potential therapeutic benefits in these life-threatening inflammatory diseases.
CalciMedica Inc. (NASDAQ:CALC) is developing novel CRAC channel inhibitors targeting life-threatening inflammatory diseases with high unmet medical needs. The company has demonstrated consistent positive clinical activity and good tolerability in multiple Phase 2 clinical trials in acute critical illnesses. CALC’s current cash runway extends into 1H26 and is expected to fund operations and completion of the ongoing KOURAGE Phase 2 trial in AKI patients. The market opportunity is substantial, with approximately 1 million target AKI population and around 100 thousand target AP population representing multi-billion US market opportunities with no approved therapies.
CalciMedica Inc. (NASDAQ:CALC) has strong intellectual property protection; their lead candidate, Auxora, has shown consistent reduction and prevention of acute respiratory failure and mortality across multiple clinical trials. In the CARPO Phase 2b trial, Auxora demonstrated positive impact on organ failure, particularly new onset severe respiratory failure, reduction of necrotizing pancreatitis, and reduction in time to medically indicated discharge and length of hospital stays. The drug has been well-tolerated in over 350 critically ill patients with no sudden unexpected serious adverse reactions reported to date. With a strong portfolio of promising pharmaceutical products, the company’s future appears bright, which is supported by significant insider purchasing in the last months.
